Argenx (ARGX)

Executive Summary

Argenx is a global immunology company pioneering FcRn blockade with its lead product, efgartigimod (Vyvgart), approved for generalized myasthenia gravis (gMG) and primary immune thrombocytopenia (ITP). Leveraging its SIMPLE Antibody platform, the company has a deep pipeline targeting severe autoimmune diseases including chronic inflammatory demyelinating polyneuropathy (CIDP), pemphigus vulgaris (PV), and systemic lupus erythematosus. Efgartigimod's subcutaneous formulation is expanding, offering patient convenience and market growth. With a strong commercial launch in gMG and ITP, Argenx is well-positioned to capture additional indications, driving long-term value. The company's robust cash position and strategic focus on immunology support continued investment in R&D and global commercialization.

Upcoming Catalysts (preview)

• Q4 2026FDA Decision on Efgartigimod for CIDP70% success
• H1 2027Phase 3 Data Readout for Efgartigimod in Pemphigus Vulgaris60% success
• Q3 2026Subcutaneous Efgartigimod Approval in New Indications (e.g., ITP)90% success